This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tuberous sclerosis complex tumor suppressor 2 (TSC2); retinoblastoma 1 (RB1)	A study in cell culture and in mice suggests that inhibiting TSC2 could help treat RB1 mutant cancers. In human RB1 mutant cancer cell lines, small hairpin RNA-mediated knockdown of <i>TSC2</i> inhibited growth compared with that seen using control shRNA. In a xenograft mouse model of <i>Rb1</i> mutant human prostate cancer, expression of <i>Tsc2</i> -targeting shRNA resulted in reduced tumor incidence compared with expression of control shRNA. Next steps include developing TSC2 inhibitors for therapeutic application.	Unpatented; available for licensing	Li, B. <i>et al. Cancer Cell</i> ; published online May 13, 2010; doi:10.1016/j.ccr.2010.03.019 Contact: Wei Du, The University of Chicago, Chicago, Ill. e-mail: wei@uchicago.edu
<i>SciBX</i> 3(20); doi:10.1038/scibx.2010.616 Published online May 20, 2010				